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Abstract 
Synovial cysts are currently classified as degenerative lesions affecting the joint capsule or adjacent 
structures. In our study we describe the results obtained in an immunohistochemical study 
comprising 18 patients with synovial cysts, performed to evaluate the pathophysiological role of 
some inflammatory cytokines such as: IL-1β, IL-6 and TNF-α. Results showed  an over-expression 
of TNF-α, IL-1β and IL which  appears to be involved in the onset and progression of the disease. 
At  the present time it is not possible to affirm that these molecules play a direct role  also due to the 
absence of further and more specific investigations. The authors therefore hypothesize that 
inhibition of inflammation may have a significant role in the pathogenesis and regression of 
synovial cysts. Hence, these inflammatory cytokines may be considered potential therapeutic 
targets. The development of synthetic inhibitors of these inflammatory factors could lead to a 
reduction in the intensity of inflammation, thus inhibiting the onset and development of the disease. 
Key words: IL-1β, IL-6, immunohistochemistry, synovial cysts, TNF-α 
 
INTRODUCTION  
Synovial cysts (also known as "ganglion", "synovial ganglion", "arthrogenic cysts") are 
benign neo-formations of the soft tissues which generally originate from the joint capsule or tendon 
sheath and contain fluid gelatinous material, usually appearing on the back of the wrist. Sometimes 
these cysts may involve neural structures, as in cases of peroneal nerve [1] or lumbar roots [2] 
involvement. 
Arthrogenic cysts are cysts that occur at the level of the joint capsule. The most frequent 
location is at the wrist. Since the joints are completely wrapped in a fibrous tissue (capsule) that 
favors the movements’ fluidity, a thinner capsular wall is responsible for a possible traumatic 
damage and so the cyst may develop in the joint. A herniation of the capsule occurs and it tends to 
move towards the superficial tissues and to form a revolving structure that we call cysts [3, 4]. 
The mechanism that gives rise to these cysts is still not clear.Synovial cysts are mostly 
found in young athletes or workers who use the wrist and hand joints a lot. In many cases synovial 
cysts are the result of joint inflammation, arthrosis or previous trauma.However, the exact role of 
inflammation in this process has not yet been studied in detail. The synovial fluid contains 
inflammatory factors such as cytokines, prostaglandins and proteases. Previous studies have shown 
that angiogenic factors are released during the formation of the synovial cysts, suggesting a possible 
correlation between the proliferation of new vessels in synovial structures and the chronic 
inflammatory process that induces the progression of synovial cysts [2, 5, 6]. However, to date, no 
previous studies have analyzed the modulation of the inflammatory process in the regression of 
synovial cysts.It has been shown that in the spinal joint tissue the induction of type 2 
cyclooxygenases (COX-2) and phospholipase A2 stimulates the biosynthesis of different 
inflammatory mediators from synovial chondrocytes (chondrocytes from synovial joints), such as 
prostaglandin E2, interleukins (IL-1, IL-6 , IL-8) and granulocyte-macrophage colony–stimulating 
factor (GM-CSF)[7]. Cox-2 inhibitors have been shown to reduce synovitis, leukocyte infiltration 
and synovial hyperplasia in animal models, reducing the expression of IL-1β, TNF-α and IL-6 [8, 
9]. Our study is based on previous experimental data that support the role played by inflammatory 
cytokines and growth factors in the development of arthrogenic synovial cysts. In the light of the 
data reported in the literature we hypothesize that inhibition of inflammation may play a significant 
role in the destiny and/or regression of arthrogenic synovial cysts. The aim of the present study was 
to evaluate the pathophysiological role of some inflammatory cytokines, such as IL-1β, IL-6 and 
TNF-α, in tissue samples of synovial cysts or tenosynovitis, obtained by surgical removal near a 
wrist joint. The main purpose of this was to evaluate the expression levels and localization of 
inflammatory cytokines by immunohistochemical analysis to identify their involvement in the 
pathology and to evaluate the possible modulation of these factors as a potential therapeutic target. 
MATERIALS AND METHODS 
Clinical evaluation 
Written informed consent concerning the donation ofhuman tissues was provided by patients 
prior to tissue acquisition, following the protocol for the acquisition of human tissues of the Ethical 
Committee of our University Hospitals which approved the study protocol. All specimens were 
acquired according to the principles of the Helsinki Declaration.  
Eighteen patients were included in the study, aged between 11 and 56 years (11 males and 7 
females), undergoing surgical treatment for the removal of wrist synovial cysts,  in the Orthopedic 
Unit of the S. Andrea Hospital in Rome. Control samples (2 specimens for each tissue fragment), 
characterized by normal palmar fascia tissues, were collected from patients undergoing hand 
surgery for Carpal Tunnel Syndrome (CTS).  
Patients with concomitant neoplastic, infectious, autoimmune diseases, peripheral vascular 
disorders or who had performed anti-inflammatory therapy in the six months prior to the operation 
were excluded. 
During excision, apart from anaesthesia, no other chemical products or pharmaceutical drugs 
were administered to the patients.  Samples  were fixed in formalin and embedded in paraffin to be 
processed for histological staining and immunohistochemistry. The sections were subjected to 
Hematoxylin & Eosin and Masson’s Trichromic staining. 
 
Immunohistochemistry 
The immunohistochemical analysis was conducted using the ABC/HRP technique 
(avidincomplexed with biotinylated peroxidase) on 4µm thick paraffin sections which were cut 
using a rotative microtome. These sections were deparaffinized and hydrated through decreasing 
ethanol series to distilled water, then subjected to microwave irradiation and immersed in citrate 
buffer (pH= 6) twice for 5 minutes each time. Subsequently, endogenous peroxidase activity was 
quenched using 0.3% hydrogenous peroxide in methanol for 30 minutes. To evaluate the 
immunolocalization of IL-1β, TNF-α and IL-6, the following antibodies were employed: i) rabbit 
anti-IL-1β polyclonal antibody (1:50, Santa Cruz Biotechnology, Santa Cruz, CA, USA); ii) mouse 
anti-TNF-α monoclonal antibody (1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA); iii) 
rabbit anti‑ IL‑ 6 polyclonal antibody (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
Incubation with the primary antibodies was performed overnight at 4º C. Optimal antibody dilution 
and incubation times were assessed in preliminary experiments. As negative control, the primary 
antibodies were omitted. After exposure to the primary antibodies all slides were rinsed twice in 
phosphate buffer (pH=7.4) and incubated for 1 hour with the appropriate secondary biotinylated 
antibody at the final dilution of 1:200. The secondary biotinylated antibodies against rabbit and 
mouse immunoglobulins were purchased from Abcam (biotinylated goat anti-mouse antibody and 
biotinylated goat anti-rabbit antibody). The slides were then incubated with peroxidase-conjugated 
avidin (Vector laboratories, Burlingame, CA, USA, Vectastain Elite ABC kit Standard*PK 6-100) 
for 30 min. Slides were washed in phosphate buffer (pH=7.4) and treated with 0.05% 3,3-
diaminobenzidine (DAB) and 0.1% H2O2. Finally, sections were counterstained with Mayer’s 
hematoxylin and dehydrated rapidly. The staining assessment was made by three experts. The 
intensity of the immune reaction was assessed microdensitometrically using an IAS 2000 image 
analyzer (Delta Sistemi, Rome, Italy) connected via a TV camera to the microscope. Twelve 
100µm2 areas were delineated in each section by measuring the diaphragm. The system was 
calibrated taking the background obtained in sections exposed to non-immune serum as zero. 
 
Statistical analysis 
Statistical analysis was performed with the Student’s t-test, using the GraphPad Prism (La 
Jolla, CA). A p-value<0.05 wasconsidered for statisticalsignificance. 
 
RESULTS 
The histopathological alterations caused by human arthrogenic synovial cysts were 
evaluated using the immunohistochemical technique. Immunohistochemical experiments have made 
it possible to visualize the distribution and localization of the cytokines analyzed in the tissue 
samples obtained by surgical removal from patients witharthrogenic synovial cysts (Table I). 
Through hematoxylin / Eosin staining it was possible to detect, in the pathological tissues, the myo-
fibroblastic proliferation site (Fig. A1-A3), not present in the control tissue (Fig. A4). In the 
pathological tissue (Fig. A1-A3) a thickening of fibroblasts and myo-fibroblasts was visible with 
areas of complete cellular overlapping. This tissue morphology is not present in normal tissue (Fig. 
A4), in which only connective tissue with dispersed fibroblasts and small blood vessels can be 
observed. Figures B1-B3 describe the immunohistochemical expression of interleukin 1β (IL-1β) in 
pathological samples,  demonstrating  positive reactions in the cytoplasm of myo-fibroblastic cells 
and in the extracellular matrix. IL-1β is completely absent in the extracellular matrix of the palmar 
control fascia specimens (Fig B4). Moreover, this pro-inflammatory cytokine is highly expressed at 
the level of the capillary endothelium, near the synovial cysts. Interleukin 6 (IL-6) is appreciable in  
extracellular matrix, both in proliferating myo-fibroblasts and in fibroblasts at the level of 
proliferative nodules in patients affected by arthrogenic synovial cysts (Fig. C1). In the normal 
tissue of palmar fascia IL-6 appears to be completely absent at the level of the loose connective 
tissue, but moderately present in the endothelial cells of the blood vessels and in the fibroblasts 
scattered in the connective tissue (Fig. C2). Unlike the other cytokines, IL-6 shows an appreciable 
localization in normal fibroblasts (Fig. C1) and a more evident cytoplasmic localization in the 
pathological ones (Fig. C2). This cytokine appears to be involved in the inflammatory process that  
leads to the activation of the fibrotic process. Therefore, IL-6 appears to be synthesized in response 
to TGF-β1 and acts by enhancing the proliferation and differentiation of fibroblasts into myo-
fibroblasts with deposition of amorphous substance in association with TGF-β1. Tumor necrosis 
factor α (TNF-α) is expressed in the extracellular matrix of the myo-fibroblastic tissueat the 
proliferation site observed in patients with synovial cysts (Fig. D1). TNF-α is present in 
pathological myo-fibroblasts and in capillary endothelial cells (Fig. D1). In the loose connective 
tissue of the normal palmar fascia this inflammatory factor is however moderately positive in the 
cytoplasm of fibroblastic cells and in the extracellular matrix (Fig. D2). This growth factor is also 
strongly expressed in the cytoplasm of secreting sweat glands (Fig. D2) in the dermis near the 
pathological proliferative nodules. 
 
DISCUSSION 
Arthrogenic synovial cysts are a benignly progressing fibro-proliferative disorder 
whichoften  lead to severe functional damage. The lack of knowledge related to the 
etiopathogenesis of the disease has meant that a specific therapy is not currently available until now. 
Therefore, it is difficult to prevent its onset or to avoid its recurrence after surgical excision. The 
absence of valid therapeutic targets has led to the development of empirical therapies, such as local 
injection of steroids [10]. Inflammation plays a fundamental role in the onset of fibrosis and this 
finding is confirmed by the presence of proinflammatory cytokines [11]. In  physiological 
conditions of wound healing or tissue repair activation of the fibrotic process occurs. During this 
process fibroblastic cells may differentiate into myo-fibroblasts, because their contractile activity is 
essential for tissue remodelling. The formation of myo-fibroblasts, controlled by a variety of growth 
factors and numerous mechanical stimuli, leads to an excessive deposition of extracellular matrix. 
Their action ends when the tissue is completely repaired or reabsorbed. In some pathological 
conditions the contractile activity of myo-fibroblasts persists and leads to tissue deformation [12]. 
IL-1β, an important pro-inflammatory cytokine, is involved in “in vitro” fibroblastic proliferation 
through the induction of the expression of transcriptional factors such as c-fos, c-jun and c-myc 
[13]. The excessive expression of IL-1β alone could be responsible for the local fibroblastic 
proliferation seen in the active phase of the disease. IL-1β seems to have an important function in 
the activation and feeding of the inflammatory process, inducing the synthesis of other cytokines 
such as IL-6 and IL-2, interferons or chemokines, which are able to attract macrophages and 
granulocytes towards the  site of inflammation. It seems probable that the mitogenic effect of IL-1β 
is enhanced by the co-expression of other factors such as TGF-β and PDGF-α/β. The combined 
expression of these growth factors are probably responsible for  fibroblastic proliferation and 
excessive deposition of an amorphous substance and accumulation of synovial fluid, a condition 
typical of the disease. In our experiments we also evaluated the level of IL-6 expression. This 
cytokine is directly involved in the activation of the initial inflammatory process which 
subsequently leads to fibrosis. The pro-inflammatory cytokine IL-6 plays an important role in the 
regulation of inflammation and acts in association with TGF-β1, thus leading to an increased pro-
fibrotic response[14, 15]. IL-6 acts by enhancing the TGF-β1 signal by increasing endocytosis 
mediated by non-lipid endosomes. This consequence is due to internalization of the TGF-β1 
receptors as a result of  binding of their ligand through endocytosis mediated by caveolin lipid 
vesicles and by non-lipid vesicles, although the TGF-β1 signal increases when the receptor 
endocytosis is mediated by non-lipidic vesicles. Therefore, IL-6 and TGF-β1 act synergistically, 
causing an increase in the expression of proinflammatory cytokines that appear to be the primary 
cause of the onset of the disease. Verjee et al. [16] reported that TNF-α at low concentrations induce 
myo-fibroblastic contraction, while at high levels it induces reduction or complete inhibition of 
myo-fibroblastic contraction. It seems that the action of TNF-α depends strictly on the TNFR 
receptor type: TNFR2 causes fibroblastic proliferation, while TNFR1 activates programmed cell 
death. TNF-α could be considered a possible therapeutic target for the treatment of the disease in 
the primary stages or in preventing relapses following surgical removal. In our experimental study 
we found that TNF-α showed a greater localization in pathological fibroblasts. Therefore, this factor 
appears to be directly involved in the fibrotic reaction and its action depends exclusively on its 
TNFR2 receptor, which is strongly expressed in pathological conditions. Based upon our 
preliminary results, local injections of anti-TNF-α drugs could be useful in preventing the 
progression of the disease or avoiding its recurrence after surgical treatment. During the involutive 
phase a high ratio of collagen III on collagen I was detected, differently from the normal 
physiological condition [17]. These experimental results suggest, therefore, a possible application of 
these pro-inflammatory factors in the identifying the degree of disease progression and in the use of 
some of these markers as prognostic factors in the follow-up of patients undergoing surgical 
resection of synovial cysts. Innovative therapies could be characterized by the combined use of 
specific inhibitors of the factors TNF-α, IL-1β and IL-6 and their receptors in order to inhibit the 
progression of the disease through inactivation of the fibrotic process. 
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FIGURE LEGENDS 
Figure A. Photomicrograph of histological preparations obtained by the HEMATOXYLIN/ EOSIN 
staining method. Fig. A1 –A3 Proliferation myofibroblast nodules (asterisks) obtained by surgical 
removal from a patient with synovial cyst (10X); Fig. A4 normal palmar band consisting 
exclusively of connective tissue with  fibroblasts and blood vessels (10X). 
 
Figure B. Photomicrographs of the immunohistochemical reaction for the inflammatory cytokine 
IL-1β. Fig. B1 –B3 Pathological tissue in which IL-1β is present in the extracellular matrix and in 
the cytoplasm of fibroblasts and myofibroblasts and in the endothelium of capillaries (B1, B2, 20X; 
B3, 40X). Myofibroblasts nodules (asterisks). Fig. B4 control tissue (20X).  
 
Figure C. Photomicrographs of the immunohistochemical reaction for the cytokine IL-6. Fig. C1-
C3 Pathological tissue in which IL6 is expressed at the level of proliferative nodules (asterisks- C1, 
C2, C3, 20X). Fig. C4 control tissue (10X). 
 
Figure D. Microphotographs of the immunohistochemical reaction for the proinflammatory 
cytokine TNF-α expressed in pathological myofibroblasts and in capillary endothelial cells (D1, D2, 
D3, 20X). Myofibroblasts nodules (asterisks). Fig. D4 control tissue (20X). 




 Table 1. Expression levels of   IL-1β, IL-6, TNF-α  in synovial cysts and control specimens, and 
respective levels of  statistical significance (t-test). 
 
 
 
 
 
 
 
 
 
The results were considered as statistically significant when P-value<0.05 
 
 
 
 
 
synovial cysts (%) 
n=15 
control specimens 
(%)  n=15 
p-value 
IL-1 65.27 ± 12.91 12.61 ± 5.51 p  < .00001 
IL-6 60.46 ± 10.70 11.66 ± 4.96 p  < .00001 
TNF- 61.80 ± 10.22 13.13 ± 5.81 p  < .00001 
